Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations

(2014) Yesid Alvarado et al.   CANCER

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

(2014) F Ravandi et al.   LEUKEMIA

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

(2013) Bernard Tawfik et al.   ANNALS OF HEMATOLOGY

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD

(2013) Koichi Takahashi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

(2013) Sabine Kayser et al.   LEUKEMIA & LYMPHOMA

Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

(2013) Casey B. Williams et al.   PHARMACOTHERAPY

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How

(2013) John Magenau et al.   Current Oncology Reports

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Azacitidine

(2012) Gillian M. Keating   DRUGS

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Acute myeloid leukaemia in the elderly: a review

(2011) Daniel A. Pollyea et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation

(2009) G. Yoshimoto et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

(2009) Farhad Ravandi et al.   LEUKEMIA RESEARCH

Relapse and death during first remission in acute myeloid leukemia

(2008) M. Yanada et al.   HAEMATOLOGICA

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

(2008) Gautam Borthakur et al.   LEUKEMIA & LYMPHOMA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE